With the improvement of HER2-targeted therapy in patients with breast cancer, there is growing interest in whether chemotherapy can be eliminated from regimens completely. Here, the authors report a phase 2 clinical trial investigating neoadjuvant zanidatamab (HER2-targeting antibody) in patients with early-stage HER2-positive breast cancer.